Dimerix Bioscience

Dimerix is a privately held drug discovery company developing a pipeline of lead compounds with highly specific activity and reduced risk of off-target effects to treat diseases in oncology, metabolic disorders, cardiovascular and inflammation.

Dimerix’ unique G-Protein Coupled Receptor Heteromer Identification Technology (GPCR-HIT) platform includes a library of novel GPCR heteromer targets, screening and profiling capabilities and knowledge of biased intracellular signalling mediated through GPCR heteromers.

This platform enables Dimerix to identify and develop the best lead compounds that target GPCR heteromers.

Dimerix CSO Associate Professor Kevin Pfleger wins the Western Australian Young Scientist of the Year Award for 2009.